Cargando…

Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer

BACKGROUND: Studies conducted in Swedish populations have shown that men with lowest prostate-specific antigen (PSA) levels at ages 44–50 years and 60 years have very low risk of future distant metastasis or death from prostate cancer. This study investigates benefits and harms of screening strategi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heijnsdijk, Eveline A M, Gulati, Roman, Tsodikov, Alex, Lange, Jane M, Mariotto, Angela B, Vickers, Andrew J, Carlsson, Sigrid V, Etzioni, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566340/ https://www.ncbi.nlm.nih.gov/pubmed/32067047 http://dx.doi.org/10.1093/jnci/djaa001

Ejemplares similares

Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas
por: Heijnsdijk, Eveline A. M., et al.
Publicado: (2022)

Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer
por: Nyame, Yaw A, et al.
Publicado: (2020)

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study
por: Carlsson, Sigrid, et al.
Publicado: (2014)

Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios
por: Getaneh, Abraham M., et al.
Publicado: (2020)

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
por: Vickers, Andrew J, et al.
Publicado: (2014)

Spotlight on prostate cancer: the latest evidence and current controversies
por: Carlsson, Sigrid, et al.
Publicado: (2015)

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
por: Wever, E M, et al.
Publicado: (2013)

Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam
por: Wever, Elisabeth M., et al.
Publicado: (2010)

Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence
por: Stattin, Pär, et al.
Publicado: (2014)

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
por: Heijnsdijk, E A M, et al.
Publicado: (2009)

A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data
por: Karlsson, Andreas, et al.
Publicado: (2019)

Active surveillance for prostate cancer
por: Shill, Daniela K., et al.
Publicado: (2021)

Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer
por: Callender, Thomas, et al.
Publicado: (2021)

Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model
por: Mühlberger, Nikolai, et al.
Publicado: (2017)

The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate
por: Kohestani, Kimia, et al.
Publicado: (2021)

Extending Age Ranges in Breast Cancer Screening in Four European Countries: Model Estimations of Harm-to-Benefit Ratios
por: Zielonke, Nadine, et al.
Publicado: (2021)

Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
por: Lodeta, Branimir, et al.
Publicado: (2023)

Statistics for health data science: an organic approach
por: Etzioni, Ruth, et al.
Publicado: (2020)

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis
por: Hupe, Marie Christine, et al.
Publicado: (2018)

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen
por: Michael, Zoe D., et al.
Publicado: (2023)

Lifetime economic burden of prostate cancer
por: Stokes, Michael E, et al.
Publicado: (2011)

Stratifying the initial prostate cancer suspicion to avoid magnetic resonance exams by sequencing men according to serum prostate‐specific antigen, digital rectal examination and the prostate‐specific antigen density based on digital rectal prostate volume category
por: Morote, Juan, et al.
Publicado: (2022)

Estimating patient health in prostate cancer treatment counseling
por: Chesnut, Gregory T., et al.
Publicado: (2023)

Cost‐effectiveness of multiparametric magnetic resonance imaging and MRI‐guided biopsy in a population‐based prostate cancer screening setting using a micro‐simulation model
por: Getaneh, Abraham M., et al.
Publicado: (2021)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Patient Perceptions of a Decision Support Tool for Men with Localized Prostate Cancer
por: Austria, Mia, et al.
Publicado: (2023)

Prostate cancer screening—when to start and how to screen?
por: Kohestani, Kimia, et al.
Publicado: (2018)

Who and when should we screen for prostate cancer? Interviews with key opinion leaders
por: Carlsson, Sigrid, et al.
Publicado: (2015)

On Risk Estimation versus Risk Stratification in Early Prostate Cancer
por: Carlsson, Sigrid V., et al.
Publicado: (2016)

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
por: Kovac, Evan, et al.
Publicado: (2020)

Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
por: Callender, Tom, et al.
Publicado: (2019)

Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer
por: Ma, Chaoran, et al.
Publicado: (2023)

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis
por: Pashayan, Nora, et al.
Publicado: (2015)

Comparative Metabolomic and Lipidomic Analysis of Phenotype Stratified Prostate Cells
por: Burch, Tanya C., et al.
Publicado: (2015)

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model
por: Pashayan, Nora, et al.
Publicado: (2018)

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
por: Ben Jemaa , Awatef, et al.
Publicado: (2010)

The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy
por: Vesely, Stepan, et al.
Publicado: (2014)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
por: Vickers, Andrew J, et al.
Publicado: (2010)

AB004. Rational and risk-stratified prostate cancer screening and treatment
por: Cooperberg, Matthew R.
Publicado: (2018)

Prostate specific antigen /
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_oovvkfhk26b2pqe5jfr6a6o4tj